Bone Biologics Corporation held its annual meeting of stockholders on May 30, 2025. Stockholders approved the election of four director nominees: Bruce Stroever, Siddhesh Angle, Robert Gagnon, and Philip Meikle. Additionally, stockholders approved an amendment to the company's 2015 Equity Incentive Plan to increase the number of shares of common stock reserved for issuance by 30,000,000 shares.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.